MGO One Seven LLC Has $3.08 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Key Points

• MGO One Seven LLC increased its stake in AstraZeneca by 10.5%, acquiring 3,968 shares to bring its total holdings to 41,905 shares, valued at approximately $3.08 million.
• AstraZeneca reported earnings of $1.09 per share, meeting consensus estimates, with revenue of $14.46 billion—a 16.1% increase from the previous year.
• The company recently announced a semi-annual dividend of $0.505 per share, with a 200.0% yield and a payout ratio of 37.97%.

MGO One Seven LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 10.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,905 shares of the company's stock after buying an additional 3,968 shares during the quarter. MGO One Seven LLC's holdings in AstraZeneca were worth $3,080,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Banque Transatlantique SA bought a new position in shares of AstraZeneca in the 4th quarter valued at about $26,000. Confluence Investment Management LLC bought a new position in shares of AstraZeneca in the 1st quarter valued at about $27,000. Larson Financial Group LLC boosted its stake in shares of AstraZeneca by 297.9% in the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after purchasing an additional 289 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of AstraZeneca in the 4th quarter valued at about $29,000. Finally, FNY Investment Advisers LLC bought a new position in shares of AstraZeneca in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Trading Up 1.2%

Shares of NASDAQ:AZN traded up $0.86 during mid-day trading on Friday, reaching $73.95. The stock had a trading volume of 9,725,399 shares, compared to its average volume of 5,003,182. The firm has a market cap of $229.34 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 1.36 and a beta of 0.36. The firm has a 50 day simple moving average of $71.55 and a two-hundred day simple moving average of $71.41. The company has a current ratio of 0.86, a quick ratio of 0.70 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business's quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company posted $1.24 EPS. On average, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date is Friday, August 8th. AstraZeneca's dividend payout ratio (DPR) is 77.44%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.